📊 OCGN Key Takeaways
Is Ocugen, Inc. (OCGN) a Good Investment?
Ocugen exhibits severe financial distress with only $1.5M revenue supporting $17.8M operating losses and 4.17x debt-to-equity leverage, creating critical solvency risk. Operating cash burn of $21.8M annually exhausts the $31.9M cash position in approximately 1.5 years, while stockholders' equity of $5.8M cannot absorb further losses. Without substantial revenue acceleration or capital restructuring, the company faces significant shareholder value destruction through dilution or insolvency.
Ocugen shows minimal revenue against extremely negative margins and sustained operating losses, resulting in negative stockholders’ equity and very weak interest coverage. Continued heavy cash burn with limited cash on hand makes the business highly dependent on external financing or near-term monetization to remain viable. While revenue grew modestly and EPS losses narrowed, the balance sheet and cash flow profile indicate elevated solvency and dilution risk.
Ocugen, Inc. Key Strengths (OCGN)
- Positive 8.8% year-over-year revenue growth indicates some commercial traction from product pipeline
- Cash position of $31.9M provides immediate operational runway for near-term obligations
- Current ratio of 1.86x demonstrates adequate short-term liquidity to cover current liabilities
- Modest YoY revenue growth (+8.8%) from a low base
- Low capital expenditure requirements support financial flexibility
- EPS loss narrowed YoY
OCGN Stock Risks: Ocugen, Inc. Investment Risks
- Operating cash burn rate of $21.8M annually with only 1.5 years of runway at current depletion rate
- Extreme leverage with 4.17x debt-to-equity ratio against deteriorating equity base of $5.8M
- Negative 1163.7% operating margin and 1250.9% net margin indicate fundamental business model dysfunction
- Minimal $1.5M revenue base insufficient to service $51.1M total liabilities or reduce debt burden
- Negative stockholders’ equity and leverage elevate solvency risk
- Severe operating losses and FCF burn; interest coverage deeply negative
- High dependence on external financing; dilution/going‑concern risk
Key Metrics to Watch
- Monthly operating cash burn trend and projected cash depletion date
- Revenue growth acceleration and near-term commercialization milestones
- Debt refinancing events and equity dilution announcements
- Cost reduction initiatives and timeline to operating breakeven
- Operating cash flow (burn rate)
- Cash & equivalents
Ocugen, Inc. (OCGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Ocugen, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
OCGN Profit Margin, ROE & Profitability Analysis
OCGN vs Healthcare Sector: How Ocugen, Inc. Compares
How Ocugen, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ocugen, Inc. Stock Overvalued? OCGN Valuation Analysis 2026
Based on fundamental analysis, Ocugen, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ocugen, Inc. Balance Sheet: OCGN Debt, Cash & Liquidity
OCGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ocugen, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.09 indicates the company is currently unprofitable.
OCGN Revenue Growth, EPS Growth & YoY Performance
OCGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.5M | -$15.4M | $-0.05 |
| Q3 2025 | $1.1M | -$11.9M | N/A |
| Q2 2025 | $1.1M | -$11.9M | N/A |
| Q1 2025 | $1.0M | -$11.9M | N/A |
| Q3 2024 | $1.1M | -$11.7M | N/A |
| Q2 2024 | $485.0K | -$11.9M | $-0.04 |
| Q1 2024 | $443.0K | -$11.9M | $-0.05 |
| Q1 2019 | N/A | -$9.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ocugen, Inc. Dividends, Buybacks & Capital Allocation
OCGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ocugen, Inc. (CIK: 0001372299)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OCGN
What is the AI rating for OCGN?
Ocugen, Inc. (OCGN) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OCGN's key strengths?
Claude: Positive 8.8% year-over-year revenue growth indicates some commercial traction from product pipeline. Cash position of $31.9M provides immediate operational runway for near-term obligations. ChatGPT: Modest YoY revenue growth (+8.8%) from a low base. Low capital expenditure requirements support financial flexibility.
What are the risks of investing in OCGN?
Claude: Operating cash burn rate of $21.8M annually with only 1.5 years of runway at current depletion rate. Extreme leverage with 4.17x debt-to-equity ratio against deteriorating equity base of $5.8M. ChatGPT: Negative stockholders’ equity and leverage elevate solvency risk. Severe operating losses and FCF burn; interest coverage deeply negative.
What is OCGN's revenue and growth?
Ocugen, Inc. reported revenue of $1.5M.
Does OCGN pay dividends?
Ocugen, Inc. does not currently pay dividends.
Where can I find OCGN SEC filings?
Official SEC filings for Ocugen, Inc. (CIK: 0001372299) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OCGN's EPS?
Ocugen, Inc. has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OCGN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Ocugen, Inc. has a D grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OCGN stock overvalued or undervalued?
Valuation metrics for OCGN: ROE of -330.4% (sector avg: 15%), net margin of -1,250.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OCGN's AI grade for 2026?
Our dual AI analysis gives Ocugen, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OCGN's free cash flow?
Ocugen, Inc.'s operating cash flow is $-21.8M, with capital expenditures of $6.0K. FCF margin is -1,422.0%.
How does OCGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,250.9% (avg: 12%), ROE -330.4% (avg: 15%), current ratio 1.86 (avg: 2).
Is Ocugen, Inc. carrying too much debt?
OCGN has a debt-to-equity ratio of 4.17x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.86 suggests adequate short-term liquidity.